Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Recurrence 1Optic Neuritis 1Neuromyelitis Optica 1Myelitis, Transverse 1Demyelinating Diseases 1

Interventions

Carboplatin 9Paclitaxel 8Gemcitabine 8Cisplatin 8Cyclophosphamide 7Fluorouracil 6Docetaxel 5Capecitabine 5Granulocyte Colony-Stimulating Factor 4Etoposide 4Vinorelbine 3Stem Cell Transplantation 3Radiotherapy 3Pemetrexed 3Melphalan 3Leucovorin 3Filgrastim 3Erlotinib Hydrochloride 3Bone Marrow Transplantation 3Bevacizumab 3umbralisib 2ublituximab 2pembrolizumab 2peginterferon alfa-2b 2fludarabine 2Whole-Body Irradiation 2Trastuzumab 2Transplantation, Homologous 2Surveys and Questionnaires 2Surgical Procedures, Operative 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Terminated × eculizumab × Clear all
NCT04155424 2024-09-25

A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder

Alexion Pharmaceuticals, Inc.

Phase 2/3 Terminated
5 enrolled 15 charts

Demyelinating Diseases, Myelitis, Transverse, Neuromyelitis Optica, Optic Neuritis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡